A. Velázquez-Campoy

Publications42
h-index22
Citations1,874
Highly Influential Citations72
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Freire
  • 150 Publications, 11,668 Citations
  • C. Gómez‐Moreno
  • 171 Publications, 3,369 Citations
  • M. Medina
  • 134 Publications, 2,568 Citations
  • J. Sancho
  • 98 Publications, 2,801 Citations
  • Publications
  • Influence
Characterization of protein-protein interactions by isothermal titration calorimetry.
Isothermal titration calorimetry (ITC) is a powerful technique to study both protein-ligand and protein-protein interactions. This methods chapter is devoted to describing protein-protein… Expand
  • 217
  • 9
Isothermal Titration Calorimetry
In the last two decades, isothermal titration calorimetry (ITC) has become the preferred technique to determine the binding energetics of biological processes, including protein‐ligand binding,… Expand
  • 210
  • 9
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes
The vast majority of HIV-1 infections in Africa are caused by the A and C viral subtypes rather than the B subtype prevalent in the United States and Western Europe. Genomic differences between… Expand
  • 148
  • 7
  • PDF
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
KNI-764 is a powerful HIV-1 protease inhibitor with a reported low susceptibility to the effects of protease mutations commonly associated with drug resistance. In this paper the binding… Expand
  • 138
  • 5
HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity.
Existing experimental as well as computational screening methods select potential ligands or drug candidates on the basis of binding affinity. Since the binding affinity is a function of the enthalpy… Expand
  • 118
  • 5
Overcoming drug resistance in HIV‐1 chemotherapy: The binding thermodynamics of Amprenavir and TMC‐126 to wild‐type and drug‐resistant mutants of the HIV‐1 protease
Amprenavir is one of six protease inhibitors presently approved for clinical use in the therapeutic treatment of AIDS. Biochemical and clinical studies have shown that, unlike other inhibitors,… Expand
  • 95
  • 5
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
The vast majority of HIV-1 infections worldwide are caused by the C and A viral subtypes rather than the B subtype prevalent in the United States and Western Europe. Genomic differences between… Expand
  • 90
  • 5
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
One of the most serious side effects associated with the therapy of HIV-1 infection is the appearance of viral strains that exhibit resistance to protease inhibitors. The active site mutant V82F/I84V… Expand
  • 99
  • 4
Structural characterization of myotoxic ecarpholin S from Echis carinatus venom.
Phospholipase A(2) (PLA(2)), a common toxic component of snake venom, has been implicated in various pharmacological effects. Ecarpholin S, isolated from the venom of the snake Echis carinatus… Expand
  • 44
  • 4
  • PDF
Protease inhibition in African subtypes of HIV-1.
Of the 42 million people infected with HIV-1 worldwide, 30 million are in Africa. However, the HIV-1 subtypes prevalent in Africa are not the same that are prevalent in North America and Western… Expand
  • 49
  • 4